The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses

Journal of Infectious Diseases

Volumn 179, Issue 3, 1999, Pages 527-537

  Markowitz, Martin ^a,b,c,d,e,g   Vesanen, Mika ^a,b,c,d,e   Tenner Racz, Klara ^a,b,c,d,e   Cao, Yunzhen ^a,b,c,d,e,f   Binley, James M ^a,b,c,d,e   Talal, Andrew ^a,b,c,d,e   Hurley, Arlene ^a,b,c,d,e   Ji, Xia ^a,b,c,d,e   Chaudhry, Rashid M ^a,b,c,d,e   Yaman, Melody ^a,b,c,d,e   Frankel, Sarah ^a,b,c,d,e   Heath Chiozzi, Margo ^a,b,c,d,e   Leonard, John M ^a,b,c,d,e   Moore, John P ^a,b,c,d,e   Racz, Paul ^a,b,c,d,e   Nixon, Douglas F ^a,b,c,d,e   Ho, David D ^a,b,c,d,e  

^a ROCKEFELLER UNIVERSITY   (United States)

^b BERNHARD NOCHT INSTITUTE FOR TROPICAL MEDICINE   (Germany)

^c ABBOTT LABORATORIES   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^e ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^f National Center for Tuberculosis Control and Prevention   (China)

^g AARON DIAMOND AIDS RESEARCH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; INDINAVIR; LAMIVUDINE; NEVIRAPINE; RITONAVIR; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ADULT; ANTIVIRAL ACTIVITY; ARTICLE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; INTESTINE LYMPHATIC TISSUE; LYMPHOID TISSUE; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; VIREMIA; VIRUS REPLICATION;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; ANTI-HIV AGENTS; DRUG THERAPY, COMBINATION; HIV-1; HOMOSEXUALITY, MALE; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; PILOT PROJECTS; RITONAVIR; RNA, VIRAL; T-LYMPHOCYTES, CYTOTOXIC; TIME FACTORS; VIREMIA; VIRUS REPLICATION; ZIDOVUDINE;

EID: 0033402781     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/314628     Document Type: Article

References (44)

1. 1. Daar ES, Moudgil T, Meyer RD, Ho DD. Transient high levels of viremia in patients with primary human immunodeficiency virus type I infection. N Engl J Med 1991;324:961-4.
2. 2. Clark SJ, Saag MS, Decker WD, et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. N Engl J Med 1991;324:954-60.
3. 3. Cooper DA, Gold J, Maclean P, et al. Acute AIDS retrovirus infection: definition of a clinical illness associated with seroconversion. Lancet 1985;1:537-40.
4. 4. Ho DD, Sargadharan MG, Resnick L, DiMarzo-Veronese F, Rota TR, Hirsch MS. Primary human T lymphotropic virus type III infection. Ann Intern Med 1985;103:880-3.
5. 5. Schacker T, Collier AC, Hughes J, Shea T, Corey L. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med 1996;125: 257-64.
6. 6. Zhu T, Mo H, Wang N, et al. Genotypic and phenotypic characterization of HIV-1 in patients with primary infection. Science 1993;261:1179-81.
7. 7. Zhang LQ, MacKenzie P, Cleland A, Holmes EC, Leigh Brown AJ, Simmonds P. Selection for specific sequences in the external envelope protein of human immunodeficiency virus type I upon primary infection. J Virol 1993;67:3345-56.
8. 8. Koup RA, Safrit JT, Cao Y, et al. Temporal association of cellular immune response with the initial control of viremia in primary HIV-1 syndrome. J Virol 1994;68:4650-5.
9. + cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type I infection. J Virol 1994;68: 6103-10.
10. 10. Mellors JW, Kingsley LA, Rinaldo CR Jr, et al. Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Ann Intern Med 1995;122:573-9.
11. 11. O'Brien TR, Blattner WA, Waters D, et al. Serum HIV-1 RNA levels and time to development of AIDS in the multicenter hemophilia cohort study. JAMA 1996;276:105-10.
12. 12. Ho DD. Viral counts count in HIV infection. Science 1996;272:1124-5.
13. 13. Schacker T, Hughes JP, Shea T, Coombs RW, Corey L. Biologic and virologic characteristics of primary HIV infection. Ann Intern Med 1998;128: 613-20.
14. 14. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immunodeficiency virus type I infection. Nature 1995;373:117-22.
15. 15. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature 1995;373:123-6.
16. 16. Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-70.
17. 17. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics of HIV-1 infected compartments during combination therapy. Nature 1997;387:188-91.
18. 18. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997;387:183-8.
19. 19. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med 1995;333:1528-33.
20. 20. Markowitz M, Saag M, Powderly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995;333:1534-9.
21. + cells per cubic millimeter. N Engl J Med 1995;333:1662-9.
22. 22. Guilick R, Mellors J, Havlir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with HIV infection and prior antiretroviral therapy. N Engl J Med 1997;337:734-9.
23. 23. Hammer S, Squires K, Hughes M, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with HIV infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1997;337:725-33.
24. 24. Carpenter CC, Hammer SM, Hirsch MS, et al. Antiretroviral therapy for HIV infection in 1997. Updated recommendations of the International AIDS Society USA panel. JAMA 1997;277:1962-9.
25. 25. Cao Y, Ho DD, Todd J, et al. Clinical evaluation of branched DNA signal amplification for quantifying HIV type I in human plasma. AIDS Res Hum Retroviruses 1995;11:353-61.
26. 26. Mulder J, McKinney N, Christopherson C, Sninsky J, Greenfield L, Kwok S. Rapid and simple PCR assay for quantification of HIV-1 RNA in plasma: application to acute retroviral infection. J Clin Microbiol 1994; 32:292-300.
27. 27. Ho DD, Moudgil T, Alam M. Quantitation of human immunodeficiency virus type I in the blood of infected persons. N Engl J Med 1989;321: 1621-5.
28. 28. Wong JK, Hezerah M, Gunthard H, et al. Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 1997;278: 1291-5.
29. 29. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoir for HIV-1 infected patients on highly active antiretroviral therapy. Science 1997;278:1295-300.
30. 30. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci USA 1997;94:13193-7.
31. 31. Saksela K, Stevens CE, Rubinstein P, Taylor PE, Baltimore D. HIV-1 messenger RNA in peripheral blood mononuclear cells as an early marker of risk for progression to AIDS. Ann Intern Med 1995;123:641-8.
32. 32. Vesanen M, Markowitz M, Cao Y, Ho DD, Saksela K. HIV-1 mRNA splicing pattern in infected persons is determined by the proportion of newly infected cells. Virology 1997;236:104-9.
33. 33. Fox C, Tenner-Racz K, Racz P, Firpo A, Pizzo P, Fauci A. Lymphoid germinal centers are reservoirs of HIV-1 RNA. J Infect Dis 1991;164:1051-7.
34. 34. Embretson J, Zupancic M, Beneke J, et al. Analysis of human immunodeficiency virus-infected tissues by amplification and in situ hybridization reveals latent and permissive infections at single-cell resolution. Proc Natl Acad Sci USA 1993;90:357-61.
35. 35. Binley JM, Klasse PJ, Cao Y, et al. Differential regulation of the antibody responses to gag and env proteins of human immunodeficiency virus type I. J Virol 1997;71:2799-809.
36. 36. Markowitz M, Cao Y, Vesanen M, et al. Recent HIV infection treated with AZT, 3TC, and a potent protease inhibitor. In: 4th Conference on Retroviruses and Opportunistic Infections: program and abstracts (Washington, DC). Alexandria, VA: Infectious Diseases Society of America, 1997:LB8.
37. 37. Markowitz M, Talal A, Vesanen M, et al. Durable suppression of virus replication with saquinavir in combination with ritonavir and double nucleoside inhibitor therapy. In: Program and abstracts: XII World AIDS Conference (Geneva), 1998.
38. 38. Vesanen M, Cao Y, Hurley A, Schluger R, Ho DD, Markowitz M. HIV-1 proviral DNA decay rate in patients treated with potent antiretroviral regimens. In: Program and abstracts: International Workshop on HIV Drug Resistance, Treatment Strategies, and Eradication (St. Petersburg, Florida), 1997.
39. 39. Morris L, Binley J, Clas B, et al. HIV-1 antigen-specific and -nonspecific B cell responses are sensitive to combination antiretroviral therapy. J Exp Med 1998;188:233-45.
40. 40. Ogg G, Jin X, Bonhoeffer S, et al. Quantitation of HIV-specific cytotoxic T lymphocytes and plasma load of viral RNA. Science 1998;279:2103-6.
41. 41. Musey L, Hughes J, Schacker T, Shea T, Corey L, McElrath MJ. Cytotoxic T-cell responses, viral load, and disease progression in early HIV-1 infection. N Engl J Med 1997;337:1267-74.
42. + T cell responses associated with control of viremia. Science 1997; 278:1447-50.
43. 43. Burton DR, Moore JP. Why do we not have an HIV vaccine and how can we make one? Nat Med 1998;4(suppl 5):495-488.
44. 44. Ho DD. Toward HIV eradication or remission: the tasks ahead. Science 1998;280:1866-7.